Literature DB >> 25037868

A close-up on the epidemiology and transmission of multidrug-resistant tuberculosis in Poland.

T Jagielski1, A Brzostek2, A van Belkum3, J Dziadek2, E Augustynowicz-Kopeć4, Z Zwolska4.   

Abstract

Multidrug-resistant tuberculosis (MDR-TB) poses a serious challenge to the global control of the disease. The purpose of this study was to characterize MDR-TB patients from Poland and to determine the extent of MDR-TB disease attributable to recent transmission. The study included all 46 patients diagnosed with MDR-TB in Poland in 2004 and followed up for 6 years (until 2011). For each patient, sociodemographic and clinical characteristics, treatment outcomes, and bacteriological data were collected by the review of medical and laboratory records. Mycobacterium tuberculosis isolates from all patients were characterized using spoligotyping, mycobacterial interspersed repetitive unit-variable number tandem repeat (MIRU-VNTR) typing, IS6110 restriction fragment length polymorphism (RFLP) analysis, and sequencing analysis of drug resistance-associated loci (katG, mabA-inhA, rpoβ, rpsL, and embB). The majority of patients were male (86.9%), 40-64 years of age (60.8%), with a history of TB treatment (84.8%), and producing smear-positive sputa (86.9%). Twenty-two (47.8%) patients suffered from concomitant diseases and 28 (60.8%) were alcohol abusers. Treatment outcome assessment revealed that 8 (17.4%) patients were cured or completed therapy, while 15 (32.6%) died of TB, 11 (23.9%) defaulted, 8 (17.4%) failed, and 1 (2.2%) was transferred and lost to follow-up. Upon genotyping, 10 (21.7%) isolates were allocated in four clusters. These were further subdivided by mutational profiling. Overall, in 6 (13%) patients, MDR-TB was a result of recent transmission. For 4 (8.7%) of these patients, a direct epidemiological link was established. The study shows that the transmission of MDR-TB occurs at a low rate in Poland. Of urgent need is the implementation of a policy of enforced treatment of MDR-TB patients in Poland.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25037868     DOI: 10.1007/s10096-014-2202-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  38 in total

1.  Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media.

Authors:  G E Pfyffer; D A Bonato; A Ebrahimzadeh; W Gross; J Hotaling; J Kornblum; A Laszlo; G Roberts; M Salfinger; F Wittwer; S Siddiqi
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

2.  Detection of mutations associated with isoniazid resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  Tomasz Jagielski; Zofia Bakuła; Katarzyna Roeske; Michał Kamiński; Agnieszka Napiórkowska; Ewa Augustynowicz-Kopeć; Zofia Zwolska; Jacek Bielecki
Journal:  J Antimicrob Chemother       Date:  2014-05-22       Impact factor: 5.790

3.  Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.

Authors:  J D van Embden; M D Cave; J T Crawford; J W Dale; K D Eisenach; B Gicquel; P Hermans; C Martin; R McAdam; T M Shinnick
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

4.  An intervention programme for the management of multidrug-resistant tuberculosis in France.

Authors:  Marie-Laure Uffredi; Chantal Truffot-Pernot; Bertrand Dautzenberg; Muriel Renard; Vincent Jarlier; Jérôme Robert
Journal:  Int J Antimicrob Agents       Date:  2007-02-14       Impact factor: 5.283

5.  Tuberculosis in London: the importance of homelessness, problem drug use and prison.

Authors:  A Story; S Murad; W Roberts; M Verheyen; A C Hayward
Journal:  Thorax       Date:  2007-02-08       Impact factor: 9.139

6.  Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance.

Authors:  I Y Gelmanova; S Keshavjee; V T Golubchikova; V I Berezina; A K Strelis; G V Yanova; S Atwood; M Murray
Journal:  Bull World Health Organ       Date:  2007-09       Impact factor: 9.408

7.  Type 2 diabetes and multidrug-resistant tuberculosis.

Authors:  Susan P Fisher-Hoch; Erin Whitney; Joseph B McCormick; Gonzalo Crespo; Brian Smith; Mohammad H Rahbar; Blanca I Restrepo
Journal:  Scand J Infect Dis       Date:  2008

8.  Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB.

Authors:  K Kliiman; A Altraja
Journal:  Eur Respir J       Date:  2009-01-22       Impact factor: 16.671

9.  Mutations in the embB gene and their association with ethambutol resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates from Poland.

Authors:  Zofia Bakuła; Agnieszka Napiórkowska; Jacek Bielecki; Ewa Augustynowicz-Kopeć; Zofia Zwolska; Tomasz Jagielski
Journal:  Biomed Res Int       Date:  2013-12-11       Impact factor: 3.411

10.  Molecular epidemiology of multidrug-resistant tuberculosis, New York City, 1995-1997.

Authors:  Sonal S Munsiff; Trina Bassoff; Beth Nivin; Jiehui Li; Anu Sharma; Pablo Bifani; Barun Mathema; Jeffrey Driscoll; Barry N Kreiswirth
Journal:  Emerg Infect Dis       Date:  2002-11       Impact factor: 6.883

View more
  7 in total

1.  Characterization of Mutations Conferring Resistance to Rifampin in Mycobacterium tuberculosis Clinical Strains.

Authors:  Tomasz Jagielski; Zofia Bakuła; Anna Brzostek; Alina Minias; Radosław Stachowiak; Joanna Kalita; Agnieszka Napiórkowska; Ewa Augustynowicz-Kopeć; Anna Żaczek; Edita Vasiliauskiene; Jacek Bielecki; Jarosław Dziadek
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 2.  Methodological and Clinical Aspects of the Molecular Epidemiology of Mycobacterium tuberculosis and Other Mycobacteria.

Authors:  Tomasz Jagielski; Alina Minias; Jakko van Ingen; Nalin Rastogi; Anna Brzostek; Anna Żaczek; Jarosław Dziadek
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

3.  Clusters of Drug-Resistant Mycobacterium tuberculosis Detected by Whole-Genome Sequence Analysis of Nationwide Sample, Thailand, 2014-2017.

Authors:  Ditthawat Nonghanphithak; Angkana Chaiprasert; Saijai Smithtikarn; Phalin Kamolwat; Petchawan Pungrassami; Virasakdi Chongsuvivatwong; Surakameth Mahasirimongkol; Wipa Reechaipichitkul; Chaniya Leepiyasakulchai; Jody E Phelan; David Blair; Taane G Clark; Kiatichai Faksri
Journal:  Emerg Infect Dis       Date:  2021-03       Impact factor: 16.126

4.  Spatial patterns of multidrug resistant tuberculosis and relationships to socio-economic, demographic and household factors in northwest Ethiopia.

Authors:  Kefyalew Addis Alene; Kerri Viney; Emma S McBryde; Archie C A Clements
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

Review 5.  Molecular clustering of patients with diabetes and pulmonary tuberculosis: A systematic review and meta-analysis.

Authors:  Francles Blanco-Guillot; Guadalupe Delgado-Sánchez; Norma Mongua-Rodríguez; Pablo Cruz-Hervert; Leticia Ferreyra-Reyes; Elizabeth Ferreira-Guerrero; Mercedes Yanes-Lane; Rogelio Montero-Campos; Miriam Bobadilla-Del-Valle; Pedro Torres-González; Alfredo Ponce-de-León; José Sifuentes-Osornio; Lourdes Garcia-Garcia
Journal:  PLoS One       Date:  2017-09-13       Impact factor: 3.240

6.  Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis.

Authors:  Emily A Kendall; Mariam O Fofana; David W Dowdy
Journal:  Lancet Respir Med       Date:  2015-11-18       Impact factor: 30.700

7.  Factors predictive of the success of tuberculosis treatment: A systematic review with meta-analysis.

Authors:  Ninfa Marlen Chaves Torres; Jecxy Julieth Quijano Rodríguez; Pablo Sebastián Porras Andrade; María Belen Arriaga; Eduardo Martins Netto
Journal:  PLoS One       Date:  2019-12-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.